Scholarlink

Introduction <p>Constipation is a prevalent and clinically significant non-motor symptom in Parkinson’s disease (PD), affecting up to 90% of patients and often preceding motor dysfunction by several years. Imbalance in the gut microbiota and reduced short-chain fatty acid (SCFA) production potentially contribute to PD pathogenesis and symptom onset. This study aimed to determine whether supplementation with SCFAs, the prebiotic 2-fucosyllactose (2-FL), or their combination alleviates constipation and improves the quality of life of individuals with PD.</p> Methods <p>In a double-blind, randomized, parallel-group clinical trial, 72 patients with PD were assigned to either SCFA, 2-FL, or combined supplementation groups for 6&#xa0;months. Constipation and quality of life were assessed using the Cleveland Clinic Constipation Score, Bristol Stool Scale, and Patient Assessment of Constipation–Quality of Life, alongside routine neurological evaluation and physical activity questionnaires.</p> Results <p>2-FL and combined supplementation significantly reduced constipation severity after 6&#xa0;months, with the combination yielding the most pronounced and sustained benefits concerning stool consistency, defecation frequency, and patient-reported outcomes. Physical activity remained unchanged and did not affect constipation-related outcomes.</p> Conclusion <p>Combined prebiotic and SCFA supplementation effectively alleviate constipation symptoms in patients with PD and improves patient quality of life. Future research should assess the long-term implications and potential disease-modifying effects.</p> Trial Registry <p>The study was retrospectively registered with the German Clinical Trials Register (DRKS) under the identifier DRKS00027061 on 19 November 2021 (<a href="https://drks.de/search/en/trial/DRKS00027061/details">https://drks.de/search/en/trial/DRKS00027061/details</a>).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prebiotics and SCFA Alleviate Parkinson’s-Related Constipation: Results from a Randomized Controlled Trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Tobias Hegelmaier,
  • Alexander Duscha,
  • Christiane Desel,
  • Lisa-Marie Würtele,
  • Jana Peplinski,
  • Diana Jauk,
  • Riccardo Troisi,
  • Martin Klietz,
  • Simon Faissner,
  • Thomas Müller,
  • Aiden Haghikia

摘要

Introduction

Constipation is a prevalent and clinically significant non-motor symptom in Parkinson’s disease (PD), affecting up to 90% of patients and often preceding motor dysfunction by several years. Imbalance in the gut microbiota and reduced short-chain fatty acid (SCFA) production potentially contribute to PD pathogenesis and symptom onset. This study aimed to determine whether supplementation with SCFAs, the prebiotic 2-fucosyllactose (2-FL), or their combination alleviates constipation and improves the quality of life of individuals with PD.

Methods

In a double-blind, randomized, parallel-group clinical trial, 72 patients with PD were assigned to either SCFA, 2-FL, or combined supplementation groups for 6 months. Constipation and quality of life were assessed using the Cleveland Clinic Constipation Score, Bristol Stool Scale, and Patient Assessment of Constipation–Quality of Life, alongside routine neurological evaluation and physical activity questionnaires.

Results

2-FL and combined supplementation significantly reduced constipation severity after 6 months, with the combination yielding the most pronounced and sustained benefits concerning stool consistency, defecation frequency, and patient-reported outcomes. Physical activity remained unchanged and did not affect constipation-related outcomes.

Conclusion

Combined prebiotic and SCFA supplementation effectively alleviate constipation symptoms in patients with PD and improves patient quality of life. Future research should assess the long-term implications and potential disease-modifying effects.

Trial Registry

The study was retrospectively registered with the German Clinical Trials Register (DRKS) under the identifier DRKS00027061 on 19 November 2021 (https://drks.de/search/en/trial/DRKS00027061/details).